U.S. Markets closed

Weekly CEO Buys Highlight

According to GuruFocus insider data, these are the largest CEO buys from the past week.

Neoleukin Therapeutics

Neoleukin Therapeutics Inc. (NASDAQ:NLTX) President and CEO Jonathan G. Drachman bought 119,047 shares on Dec. 20 for an average price of $8.40. The share price has increased by 45% since then.

The biopharmaceutical company develops immunotherapies using protein design technology. The company's lead product candidate is NL-201, a computationally-designed de novo protein therapeutic for the treatment of IL-2/IL-15 cancer immunotherapy. It also engages in research activities for the treatment of autoimmunity and allergy. The company was formerly known as Aquinox Pharmaceuticals Inc. and changed its name to Neoleukin Therapeutics in August.


The company has a market cap of $592 million. Its shares traded at $12.18 as of Dec. 27. The net loss for the third quarter was $59.1 million, compared to a net loss of $15 million in the third quarter of 2018.

Baker Bros. Advisors LP bought 3,017,542 shares on Dec. 20 for an average price of $8.4.

Urstadt Biddle Properties

Urstadt Biddle Properties Inc. (NYSE:UBP) President, CEO and 10% owner Willing L. Biddle bought 37,000 shares on Dec. 23 for an average price of $18. The stock has gained 7.94% since then.

Urstadt Biddle Properties is a real estate investment trust is engaged in the acquisition, ownership and management of commercial real estate. Its properties consist of neighborhood and community shopping centers and office buildings.

The company has a market cap of $921 million. Its shares traded at $19.43 with a price-earnings ratio of 34.27 as of Dec. 27. Net income for the three months ended July 31 was $11.43 million, compared to $9.78 million for the same period of 2018.

Biddle also sold 37,000 shares on Dec. 23 for an average price of $18. Since then, the stock has risen 7.94%.

Director and 10% owner Catherine U. Biddle bought 37,000 shares on Dec. 23 for an price of $18 and sold 37,000 shares on Dec. 23 at a price of $18.

OPKO Health

OPKO Health Inc. (NASDAQ:OPK) CEO, Chairman and 10% owner Phillip Frost bought 100,000 shares on Dec. 19 for an average price of $1.48. Since then, the stock has gained 1.35%.

OPKO Health is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a global supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. The company's bio-reference testing business consists of routine testing and esoteric testing. Routine tests measure various health parameters, such as the functions of the heart, kidney, liver, thyroid and other organs.

The company has a market cap of $998 million. Its shares traded at $1.50 as of Dec. 27. Net loss for the third quarter was $62.01 million, compared to a net loss of $27.66 million last year.

Frost also bought 50,000 shares on Dec. 9 at a price of $1.59; 100,000 shares on Dec. 11 at a price of $1.5; 75,000 shares on Dec. 17 at a price of $1.54; and 150,000 shares on Dec. 18 at a price of $1.5.

Corporate Office Properties Trust

Corporate Office Properties Trust (NYSE:OFC) President and CEO Stephen E. Budorick bought 514 shares on Dec. 26 at a price of $29.19. The share price has risen 0.72% since then.

The REIT acquires, manages and leases office and data center properties throughout the U.S. The majority of the company's real estate portfolio is composed of office buildings in the Baltimore-Washington Corridor and Northern Virginia area. The company derives nearly all of its income in the form of rental revenue from tenants. Most of its revenue comes from the leasing of properties to U.S. government agencies and its contractors in the national security, defense and IT sectors, such as Northrop Grumman (NOC) and Boeing (BA). Regional offices in urban submarkets make also make up a sizable percentage of COPT's total square footage.

The company has a market cap of $3.3 billion. Its shares traded at $29.40 with a price-earnings ratio of 19.74 as of Dec. 27. Net income for the three months ended Sept. 30 was $23.25 million, compared to $20.32 million for the prior-year period.

Budorick also bought 1,063 shares on Dec. 17 at a price of $28.22; 1,562 shares on Dec. 19 at a price of $28.78; 509 shares on Dec. 20 at a price of $29.47; and 513 shares on Dec. 23 at a price of $29.24.

Provention Bio

Provention Bio Inc. (NASDAQ:PRVB) President and CEO Ashleigh Palmer bought 2,075 shares on Dec. 20 at a price of $11.39. Since then, the price of the stock has increased by 26.25%.

Provention Bio is a clinical-stage biopharmaceutical company leveraging a drug development strategy that is focused on the prevention or interception of immune-mediated disease. Provention aims to develop therapeutic candidates targeting the high morbidity, mortality and escalating costs of autoimmune and inflammatory diseases, including Type 1 diabetes, Crohn's disease, celiac disease and lupus.

The company has a market cap of $685 million. Its shares traded at $14.38 as of Dec. 27. Third-quarter 2019 net loss was $9.77 million compared to net loss of $5.39 million for the prior-year quarter.

Chief Medical Officer and Chief Operating Officer Eleanor Ramos bought 2,000 shares on Dec. 26 at a price of $14.34. The share price has risen 0.28% since then.

Chief Scientific Officer Francisco Leon bought 2,000 shares on Dec. 16 at a price of $11.92. Since then, the stock has climbed 20.64%.

For the complete list of stocks bought by their company CEOs, go to CEO Buys.

Disclosure: I do not own stock in any of the companies mentioned in the article.

GuruFocus 15-year anniversary promotion

The holiday season is here, and so is GuruFocus's 15-year anniversary! In order to celebrate, we are offering an exclusive holiday discount of up to 30% off on our GuruFocus Premium Membership.

Join now to get GuruFocus Premium membership for only $399/Year! In addition, save an extra $100 when you upgrade to our PremiumPlus Membership, and enjoy $100 off the price of each additional region you add to the subscription.

Don't miss out on this once-in-a-decade deal! You can sign up for the discount price by clicking this link. Happy holidays!

This article first appeared on GuruFocus.